StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Biogen (BIIB) Trades Lower on Eli Lilly (LLY) Solanezumab Failure
November 23, 2016 6:52 AM
Biogen (NASDAQ: BIIB) is trading down 1% in pre-open trade ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
FDA
Trader Talk
Next Articles
Biogen (BIIB) PT Lowered to $355 at Leerink Partners on Reduced Aducanumab Probability of Success
November 25, 2016 8:52 AM
Eli Lilly (LLY) PT Cut to $92 at Leerink Partners
November 23, 2016 2:57 PM
BMO Capital Downgrades Eli Lilly (LLY) to Market Perform Following Sola's Failure
November 23, 2016 1:48 PM
Sola News Negative for Biogen (BIIB) as Latest in Numerous Failures for the Mechanism - Baird
November 23, 2016 10:40 AM
Mizuho Sees Near-Term Trading Opportunity in Biogen (BIIB) Amid Weakness
November 23, 2016 9:48 AM
Sola Failure Decreases Value of Biogen's (BIIB) Aducanumab - BMO Capital
November 23, 2016 9:27 AM
Eli Lilly Sola Failure is a 'Serious Blow' to Biogen (BIIB) and Others in AD Field - Leerink
November 23, 2016 7:57 AM
Eli Lilly & Co. (LLY) AD Portfolio Uncertain Following Sola Failure - Leerink
November 23, 2016 7:48 AM
Eli Lilly & Co. (LLY) CEO Lechleite Not Concerned About Dividend - CNBC
November 23, 2016 7:22 AM
Eli Lilly & Co. (LLY) Sinks 11% on Solanezumab Failure
November 23, 2016 6:54 AM
